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OBJECTIVES We sought to characterize the presenting characteristics of patients with previous coronary
artery bypass graft surgery (CABG) and acute myocardial infarction (AMI) and to determine
the angiographic success rate and clinical outcomes of a primary percutaneous transluminal
coronary angioplasty (PTCA) strategy.
BACKGROUND Patients who have had previous CABG and AMI comprise a high risk group with decreased
reperfusion success and increased mortality after thrombolytic therapy. Little is known about
the efficacy of primary PTCA in AMI.
METHODS Early cardiac catheterization was performed in 1,100 patients within 12 h of onset of AMI
at 34 centers in the prospective, controlled Second Primary Angioplasty in Myocardial
Infarction trial (PAMI-2), followed by primary PTCA when appropriate. Data were collected
by independent study monitors, end points were adjudicated and films were read at an
independent core laboratory.
RESULTS Of 1,100 patients with AMI, 58 (5.3%) had undergone previous CABG. The infarct-related
vessel in these patients was a bypass graft in 32 patients (55%) and a native coronary artery
in 26 patients. Compared with patients without previous CABG, patients with previous
CABG were older and more frequently had a previous myocardial infarction and triple-vessel
disease. Coronary angioplasty was less likely to be performed when the infarct-related vessel
was a bypass graft rather than a native coronary artery (71.9% vs. 89.8%, p 5 0.001);
Thrombolysis in Myocardial Infarction trial (TIMI) flow grade 3 was less frequently achieved
(70.2% vs. 94.3%, p , 0.0001); and in-hospital mortality was increased (9.4% vs. 2.6%, p 5
0.02). As a result, mortality at six months was 14.3% versus 4.1% in patients with versus
without previous CABG (p 5 0.001). By multivariate analysis, independent determinants of
late mortality in the entire study group were advanced age, triple-vessel disease, Killip class
and post-PTCA TIMI flow grade ,3.
CONCLUSIONS Reperfusion success of a primary PTCA strategy in patients with previous CABG, although
favorable with respect to historic control studies, is reduced as compared with that in patients
without previous CABG. New approaches are required to treat patients with previous CABG
and AMI, especially when the infarct-related vessel is a diseased saphenous vein graft. (J Am
Coll Cardiol 2000;35:605–11) © 2000 by the American College of Cardiology
The effective restoration of anterograde coronary blood flow
during evolving acute myocardial infarction (AMI) has been
shown to salvage myocardium and prolong survival (1,2).
Although the efficacy of thrombolytic therapy is established
in patients with native coronary artery occlusion, reperfusion
success rates in patients with previous coronary artery bypass
graft surgery (CABG) is less well characterized but thought
to be markedly reduced given the large amount of grumous
atherosclerotic material and thrombus burden with limited
runoff found in occluded saphenous vein grafts (3). In
contrast, although randomized trials have demonstrated that
percutaneous transluminal coronary angioplasty (PTCA)
results in higher patency with lower rates of death, reinfarc-
tion and stroke as compared with thrombolytic therapy (4),
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few patients with previous CABG were enrolled in these
studies, and the relative efficacy of PTCA in patients with
AMI and previous CABG is unknown. Because ;3% to 5%
of saphenous vein grafts fail per year and 3% of patients with
previous CABG develop AMI per year (5–7), identifying
and optimizing treatment for patients with previous CABG
and AMI is increasingly important, especially as the total
number of patients with previous CABG continues to rise.
In the Second Primary Angioplasty in Myocardial Infarc-
tion trial (PAMI-2), 1,100 consecutive patients with AMI
undergoing primary PTCA at 34 international centers were
prospectively enrolled in a controlled, randomized study
(8,9). Patients who had CABG previously were actively
recruited. The present analysis was therefore performed to
characterize the presenting characteristics and outcomes
after primary PTCA in patients with previous CABG.
METHODS
The PAMI-2 trial. As previously described (8,9), 1,100
consecutive patients with AMI ,12 h in duration who were
not treated with antecedent thrombolytic therapy were
enrolled into the prospective, randomized PAMI-2 trial and
underwent primary PTCA with a mechanical reperfusion
strategy. Study criteria were deliberately nonrestrictive, al-
lowing entry of patients of any age, with any electrocardio-
graphic pattern of AMI. Major exclusion criteria consisted
of cardiogenic shock, absolute contraindications to aspirin
or heparin, previous use of thrombolytic therapy during the
same hospital period and refusal or inability to provide
written, informed consent. After arteriography and left
ventriculography, PTCA was performed, if appropriate,
using standard equipment and techniques (8–10). However,
per protocol, PTCA was deferred in selected patients for
either medical therapy or bypass surgery, on the basis of
anatomic and clinical considerations (8–10).
Patients were also risk stratified after PTCA into high
and low risk groups, as previously described (5,6). High risk
patients were subrandomized to standard care versus a 36-
to 48-h course of intraaortic balloon counterpulsation (8),
and low risk patients were subrandomized to standard care
versus an accelerated hospital discharge strategy (10). As
reported, the primary clinical end points of death, reinfarc-
tion, infarct-related artery reocclusion or postadmission
new-onset congestive heart failure or sustained hypotension
were not affected by the randomization strategies (8,9),
permitting analysis of the combined study group. Of the
1,100 enrolled patients, 192 (17%) were ineligible for
randomization and were followed in a parallel registry. The
study cohort of the present analysis includes all 1,100
enrolled patients (randomized plus registry).
Definitions. “Reinfarction” was defined as recurrent clini-
cal symptoms in association with any increase in creatine
kinase, MB fraction (CK-MB) above its previous nadir.
“Recurrent ischemia” was defined as clinical symptoms
associated with either new electrocardiographic ST segment
or T wave changes, hypotension, new murmur, CK-MB
elevation or necessity for urgent repeat PTCA or CABG.
“Target vessel revascularization” (TVR) was defined as the
performance of CABG or a repeat percutaneous interven-
tion of the infarct-related vessel after the index procedure.
Data collection and statistical analysis. Clinical data were
collected prospectively and independently verified at each
site by study monitors. Follow-up was performed by phy-
sician office visits and study nurse interviews. All adverse
events were adjudicated at the data coordinating center after
review of original source documentation. Independent core
laboratory angiographic analysis was performed by a tech-
nician who had no knowledge of the randomization scheme.
Diameter stenosis was determined by electronic calipers and
TIMI flow grades by visual assessment (11). Flow grade 3
(TIMI) was defined as complete filling of the distal vessel by
the third cardiac cycle. Global left ventricular ejection
fraction was calculated by the area–length method (12).
Categoric variables were compared by using chi-square
analysis or the Fisher exact test. Continuous variables are
presented as the mean value 6 SD and were compared by
using the Student t test or Mann-Whitney U test. All p
values are two-tailed. The independent correlates of in-
hospital events were examined using forward, stepwise
logistic regression analysis. Follow-up clinical events were
analyzed with actuarial methods, and Kaplan-Meier curves
were constructed. The influence of baseline demographic
and angiographic variables on late clinical events during the
follow-up period was evaluated with the log-rank test. Cox
proportional hazard regression was then used to determine
the independent predictors of late adverse events.
RESULTS
Baseline features. Of 1,100 patients with AMI, 58 (5.3%)
had previous CABG. Compared with patients without
previous CABG, patients with previous CABG were older,
more frequently had hyperlipidemia, previous myocardial
infarction and triple-vessel disease and were less likely to be
current cigarette smokers (Table 1). Other baseline clinical
and angiographic characteristics were similar between the
two groups.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
CK-MB 5 creatine kinase, MB fraction
PAMI 5 Primary Angioplasty in Myocardial Infarc-
tion trial
PTCA 5 percutaneous transluminal coronary
angioplasty
t-PA 5 tissue-type plasminogen activator
TIMI 5 Thrombolysis in Myocardial Infarction trial
TVR 5 target vessel revascularization
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Cardiac catheterization and primary PTCA. Of the 58
patients with previous CABG, the infarct-related vessel was
a bypass graft conduit in 32 (55%) (including 31 saphenous
vein grafts and one left internal mammary artery) and a
native coronary artery in 26 (45%). The early cardiac
catheterization laboratory findings and results appear in
Tables 2 and 3. Coronary angioplasty was performed in 89%
of patients with a native coronary artery infarct-related
vessel and in only 72% of patients in whom the infarct vessel
was a bypass graft (p 5 0.001). Coronary angioplasty was
not attempted in nine patients in whom a saphenous vein
graft was the infarct vessel, because of unfavorable anatomy
(n 5 7: three treated with intragraft urokinase, two treated
conservatively and two referred for nonemergent repeat
Table 1. Baseline Characteristics of 1,100 Patients With Versus Without Previous Coronary




(n 5 1,042) p Value
Demographic features
Age (years) 65.4 6 9.6 59.8 6 12.3 0.0007
Female gender 24.1% 26.5% 0.70
Hypertension 50.0% 52.7% 0.69
Hypercholesterolemia 55.4% 34.8% 0.002
Diabetes mellitus 22.4% 15.8% 0.18
Current cigarette smoking 17.2% 42.8% ,0.0001
Previous myocardial infarction 57.1% 15.2% ,0.0001
Admission Killip class $2 19.6% 13.8% 0.22
Symptom onset to hospital arrival (min) 133 6 148 151 6 177 0.45
Hospital arrival to reperfusion (min) 280 6 165 276 6 165 0.86
Angiographic features
No. of diseased epicardial coronary arteries
One 8.6% 61.8%





LCx 6.8% 11.1% 0.82
RCA 55.1% 54.0%
Indeterminate 0% 0.1%
Data are presented as the mean value 6 SD or percentage of patients.
CABG 5 coronary artery bypass graft surgery; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex
coronary artery; LMCA 5 left main coronary artery; RCA 5 right coronary artery.
Table 2. Early Cardiac Catheterization Outcomes and Findings in Patients With Versus




(n 5 1,042) p Value
Left ventricular ejection fraction 53 6 16% 53 6 12% 0.71
Diameter stenosis at baseline 94 6 11% 96 6 8% 0.14
TIMI flow grade at baseline
0/1 71.4% 79.6%
2 18.2% 12.4% 0.38
3 10.4% 8.0%
PTCA performed 79.3% 89.8% 0.01
Diameter stenosis after PTCA 34 6 21% 26 6 36% 0.15
TIMI flow grade after PTCA
0/1 4.6% 1.8%
2 14.0% 3.9% 0.0007
3 81.4% 94.3%
Data are presented as the mean value 6 SD or percentage of patients.
CABG 5 coronary artery bypass graft surgery; PTCA 5 percutaneous transluminal coronary angioplasty; TIMI 5
Thrombolysis in Myocardial Infarction trial.
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surgery) or spontaneous reperfusion with TIMI flow grade
3 (n 5 2, treated medically). Compared with primary
PTCA of native coronary arteries, PTCA of bypass graft
infarct vessels resulted in significantly lower rates of TIMI
flow grade 3 with greater postprocedural thrombus noted
(Table 3). Considering all patients, including those achiev-
ing patency by either primary PTCA, emergent CABG or
spontaneous reperfusion, TIMI flow grade 3 was restored in
70.8% of bypass graft conduits versus 93.2% of native
coronary vessels (p , 0.0001) and in 81.8% of patients with
previous CABG versus 93.1% of those without previous
CABG (p 5 0.005).
In-hospital outcomes. As seen in Table 4, patients with
previous CABG undergoing a primary PTCA strategy had
significantly greater in-hospital mortality than did patients
without previous CABG, especially if the infarct-related
vessel was a bypass conduit. However, by logistic regression
analysis of 18 baseline clinical and angiographic variables, only
advanced age (p 5 0.004), triple-vessel disease (p 5 0.004) and
Killip class $2 (p 5 0.02) were independent predictors of
in-hospital mortality; infarct vessel type (bypass graft vs. native
artery) was not independently related to mortality (odds ratio
1.4 [95% confidence interval 0.6 to 4.8], p 5 0.44). Other than
mortality, major adverse in-hospital events occurred with
similar frequency in the two groups (Table 4), except for a
greater frequency of congestive heart failure in patients with
bypass graft occlusion.
Considering only those 58 patients with previous CABG,
TIMI flow grade 3 was restored in 70.2% of patients with vein
graft occlusion versus 95% of patients with native vessel disease
(p 5 0.03), which was associated with a trend toward increased
in-hospital mortality (9.4% vs. 3.8%, p 5 NS).
Late clinical events. Of 1,069 patients surviving the initial
hospital period, late follow-up was available in 1,030
(96.4%) at a mean time of 8.4 6 4.8 months. As seen in
Figures 1 and 2, cumulative late survival (including in-
hospital events) was significantly reduced after primary
PTCA for AMI in patients with previous CABG, especially
if the infarct-related vessel was a bypass graft. By Cox
regression analysis, the independent predictors of cumula-
tive late mortality were advanced age (p , 0.0001), triple-
vessel disease (p 5 0.005) and Killip class $2 (p 5 0.04);
infarct vessel type (bypass graft vs. native artery) was not
independently related to mortality (odds ratio 1.3 [95%
confidence interval 0.5 to 6.2], p 5 0.49). When the model
was run for only those patients undergoing primary PTCA,





(n 5 1,068) p Value
PTCA performed 71.9% 89.8% 0.001
Diameter stenosis after PTCA 35 6 22% 26 6 35% 0.25
Maximal balloon size (mm) 3.6 6 1.3 3.1 6 0.5 ,0.0001
Maximal balloon pressure (atm) 8.0 6 3.8 7.9 6 2.7 0.89
TIMI flow grade after PTCA
0/1 4.3% 1.9%
2 25.5% 3.8% ,0.0001
3 70.2% 94.3%
Type $B dissection present after PTCA 30.4% 25.5% 0.62
Thrombus present after PTCA 30.4% 9.4% ,0.0001
Adjunctive intravessel urokinase 17.4% 9.7% 0.22
Data are presented as the mean value 6 SD or percentage of patients. Abbreviations as in Table 2.








(n 5 1,068) p Value
Death 6.9% 2.6% 0.05 9.4% 2.6% 0.02
Reinfarction 1.7% 4.2% 0.35 3.1% 4.1% 0.78
Repeat PTCA 5.2% 8.3% 0.40 6.3% 8.1% 0.70
CABG 7.0% 11.1% 0.53 6.5% 11.0% 0.42
MACE 15.5% 19.4% 0.47 21.9% 19.1% 0.69
Stroke 0% 0.9% 0.52 0% 0.8% 0.88
Recurrent ischemia 15.5% 11.3% 0.33 15.6% 11.4% 0.46
Congestive heart failure* 15.5% 12.6% 0.51 25.0% 12.4% 0.03
*Developing after hospital admission. Data are presented as percentage of patients.
MACE 5 major adverse cardiac events (i.e., death, reinfarction or target vessel revascularization); other abbreviations as in Table 2.
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establishment of TIMI flow grade 3 was also predictive of
late survival (p , 0.05).
DISCUSSION
Acute myocardial infarction in patients with previous
CABG. In the present trial, 58 (5.3%) of 1,100 patients
with AMI had previously undergone CABG, similar to the
5% to 15% incidence found in previous series (3,13,14).
Patients with previous CABG and AMI represent a high
risk subset, with greater mortality, as compared with pa-
tients without previous CABG (15–17). Patients with
previous CABG, however, have been excluded from many
previous thrombolytic trials because of a perceived lack of
efficacy (2,17,18). In the Global Utilization of Streptokinase
and TPA for Occluded Arteries (GUSTO-I) angiographic
substudy, 48 patients (2.5%) had saphenous vein graft
occlusion (19). Flow grade 2 or 3 (TIMI) was established in
48% of patients with vein graft AMI (including only 34%
with TIMI flow grade 3), versus 69% of patients with native
coronary occlusion (p , 0.01). Saphenous vein graft occlu-
sion was an independent determinant of thrombolytic fail-
ure (19). Similarly, thrombolytic therapy resulted in TIMI
flow grade 2 or 3 in only 47% of patients with previous
CABG, versus 65% of patients without previous CABG in
the Duke University experience. Thus, reperfusion rates of
occluded saphenous vein grafts after thrombolytic therapy
are lower than those rates in native vessels, and mortality has
remained high (3).
Primary PTCA in patients with previous CABG. Before
the PAMI-2 trial, scant data existed to judge the efficacy of
primary PTCA in patients with previous CABG. With 58
patients with previous CABG undergoing a primary PTCA
strategy, PAMI-2 represents the largest multicenter study to
date in which the utility of this therapy can be evaluated in
this important subset, and it is the only study to employ an
independent angiographic core laboratory. Similar to
thrombolytic therapy, PTCA success in PAMI-2 was also
found to be notably lower in patients in whom the infarct-
related vessel was a bypass graft rather than a native
coronary artery. At least two reasons underlie this finding.
First, given the frequent presence of unfavorable anatomy
and extensive thrombus burden, PTCA was only attempted
in 72% of patients with a bypass graft infarct vessel, as
compared with 89% of patients with native coronary artery
occlusions (p 5 0.001). Second, when PTCA was at-
tempted, TIMI flow grade 3 was restored in only 70% of
bypass grafts, as compared with 94% of native coronary
arteries (p , 0.0001), which may be related to extensive
thrombus and atherosclerosis burden with limited runoff,
graft ectasia and increased rates of distal embolization (3).
Local infusion of urokinase was also more likely to be used
with vein graft disease as compared with native coronary
artery occlusion, either for primary reperfusion or as an
adjunct to angioplasty, although its utility in this setting is
speculative (20). In the only other published experience of
primary PTCA in .15 patients with previous CABG,
O’Keefe et al. (13) reported an 86% rate of TIMI flow grade
2 or 3 in patients with previous CABG, as compared with
94% in native coronary artery occlusion (p , 0.0001).
Clinical outcomes after primary PTCA in patients with
previous CABG. In the present study, patients with pre-
vious CABG undergoing primary PTCA had significantly
greater in-hospital and late mortality than did patients
Figure 1. Survival curves (Kaplan-Meier estimates) for 1,100
patients with AMI treated with primary PTCA, stratified by
whether or not the patient had undergone CABG before the index
hospital admission. Event rates are cumulative (including in-
hospital and postdischarge outcomes). Bold lines represent pa-
tients with previous CABG; standard lines represent patients
without previous CABG. reMI 5 repeat myocardial infarction.
Figure 2. Survival curves, stratified by whether or not the infarct-
related vessel was a bypass graft conduit or native coronary artery.
Event rates are cumulative (including in-hospital and postdis-
charge outcomes). Bold lines represent bypass graft infarct vessels;
standard lines represent native coronary artery infarct vessels.
reMI 5 repeat myocardial infarction.
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without previous CABG, consistent with earlier studies
(14–16). In these studies, the increased mortality in patients
with previous CABG and AMI was noted, despite the fact
that infarct size tended to be smaller, an observation
attributed to the more frequent presence of high risk
features such as multivessel disease and previous myocardial
infarction in patients with previous CABG (3,14–16). In
PAMI-2, multivariate analysis of 1,100 patients with AMI
identified three major factors independently related to
short-term and late mortality: advanced age, triple-vessel
disease and Killip class $2 on hospital admission, features
that were more frequently present in patients with previous
CABG. Patients with previous CABG were also much
more likely to have had a myocardial infarction before,
contributing to the propensity for congestive heart failure.
Thus, much of the poor prognosis in patients with previous
CABG may be explained by the coexistence of adverse high
risk characteristics, although the relatively low TIMI flow
grade 3 rates achieved after primary PTCA, when the
infarct-related vessel is a bypass graft, is contributory (21).
In contrast to mortality, the overall rates of death,
reinfarction and TVR at a mean 8.0 months of follow-up
were nearly identical between patients with and those
without previous CABG after primary PTCA, with the
excess mortality in patients with bypass graft infarction
counterbalanced by a trend toward less late TVR.
No randomized trial has directly compared the outcomes
of primary PTCA and thrombolytic therapy in patients with
previous CABG. In the PAMI-1 trial (22), PTCA was
successful in five of five patients with previous CABG, none
of whom developed recurrent ischemia or reinfarction or
died. In contrast, three (42%) of seven patients treated with
tissue-type plasminogen activator (t-PA) had recurrent
ischemia in the study (p 5 0.09 vs. PTCA), two of whom
died or developed reinfarction (23).
Study limitations. The major limitation of this study is
that newer treatment modalities, including glycoprotein
IIb/IIIa inhibitors and coronary stents, were not used in
PAMI-2. However, there is no present evidence that
glycoprotein IIb/IIIa antagonists improve TIMI flow or
reduce mortality in patients with AMI undergoing primary
PTCA (24), and recent studies suggest they are relatively
ineffective in saphenous vein graft intervention (25). Com-
pared with PTCA, stent implantation may improve long-
term graft patency (26). However, in the recently completed
PAMI stent randomized trial, although coronary stents, as
compared with balloon angioplasty, reduced late restenosis
in native vessel AMI, early stent implantation resulted in
lower TIMI flow grade 3 rates, with concordant trends
toward increased early and late mortality (27), an effect that
may be exacerbated in heavily diseased saphenous vein
grafts. Future studies will therefore be required to determine
whether stents or glycoprotein IIb/IIIa inhibitors, or both,
can indeed improve on the benchmark results of balloon
angioplasty in patients with previous CABG and AMI, as
reported in this study.
Although this report is the largest multicenter experience
with primary PTCA in patients with previous CABG to
date, the relatively modest sample size of patients with
previous CABG and saphenous vein graft occlusion consti-
tutes a second limitation. Nonetheless, the event rates were
sufficiently high in these patients so that the point estimates
for TIMI flow and mortality were statistically significant
and highly different from those of patients without previous
CABG and native coronary occlusion. The present analysis
may have limited power, however, to detect other secondary
end point differences between the groups, as well as any
possible benefits of intraaortic balloon counterpulsation in
patients with vein graft occlusion.
Clinical implications. Patients with previous CABG and
AMI remain at high risk for early and late mortality, despite
the contemporary practice of primary PTCA, in large part
because of their late age at presentation, the presence of
diffuse coronary artery disease and left ventricular dysfunc-
tion. Although the 71% TIMI grade 3 flow rate found in
the present trial with the early catheterization approach
(achieving reperfusion by primary PTCA, operation or with
conservative medical care) is approximately double that
reported for accelerated t-PA (19), it is strikingly lower than
the $90% TIMI grade 3 flow rates achieved with primary
PTCA of native coronary arteries (27). Thus, although the
present study supports withholding thrombolysis for the
preferential triage of patients with previous CABG to early
cardiac catheterization, followed by primary PTCA when
appropriate, more effective strategies are required for acute
saphenous vein graft occlusion. Favorable results of pilot
studies in small numbers of patients with AMI and vein
graft occlusion treated with either extraction atherectomy
(Transluminal Extraction Catheter, InterVentional Tech-
nologies, Inc., San Diego, California) or rheolytic throm-
bectomy (Angiojet, Possis Medical, Inc., Minneapolis,
Minnesota) suggest that mechanical thrombolysis may have
a role before definitive angioplasty (28–30). Randomized
trials will be required to establish the clinical utility of these
approaches, as well as stents, distal protection devices and
adjunctive pharmacologic agents, in patients with vein graft
occlusion undergoing mechanical reperfusion therapy for
AMI.
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